Euronext announces its new strategic plan, “Innovate for Growth 2027” Read more about Euronext announces its new strategic plan, “Innovate for Growth 2027”
LACROIX : Consolidated revenue of €494,2 million for the first 9 months of FY 2024, down 6.3% on a like-for-like basis. Read more about LACROIX : Consolidated revenue of €494,2 million for the first 9 months of FY 2024, down 6.3% on a like-for-like basis.
KLÉPIERRE: INFORMATION REGARDING THE TOTAL VOTING RIGHTS AND SHARES OF KLÉPIERRE SA AS OF OCTOBER 31, 2024 Read more about KLÉPIERRE: INFORMATION REGARDING THE TOTAL VOTING RIGHTS AND SHARES OF KLÉPIERRE SA AS OF OCTOBER 31, 2024
Transgene Reports Business, Pipeline and Financial Update for Q3 2024 Read more about Transgene Reports Business, Pipeline and Financial Update for Q3 2024
GTT: Monthly disclosure of the total number of voting rights and shares composing the share capital Read more about GTT: Monthly disclosure of the total number of voting rights and shares composing the share capital
Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024 Read more about Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024